AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28614995
Drug: Tobramycin inhalation
RxNorm normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin inhalation powder (TIP) via T-326 inhaler
Trial: 28614995
Drug: Tobramycin inhalation
RxNorm normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin inhalation solution (TIS) via nebulizer
Trial: 28614995
Drug: Tobramycin inhalation
RxNorm normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin inhalation solution (TIS) and Colistimethate sodium (COLI) via nebulizers
Trial: 28615265
Drug: Nutritional intake
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional intake from food and supplements; specific details on dosage and duration not available.
Trial: 28615279
Drug: MOAT (Medicines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOAT (Medicines Optimisation Assessment Tool)
Trial: 28615304
Drug: Ibuprofen exposure
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen exposure
Trial: 28615304
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no ibuprofen exposure)
Trial: 28616853
Drug: Ceramide dominant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceramide dominant therapeutic moisturizer applied twice daily for 12 weeks
Trial: 28618864
Drug: Bacteroidetes/Firmicutes-ratio and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacteroidetes/Firmicutes-ratio and peripheral insulin sensitivity in men
Trial: 28618864
Drug: Bacteroidetes/Firmicutes-ratio and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacteroidetes/Firmicutes-ratio and peripheral insulin sensitivity after adjustment
Trial: 28618864
Drug: Bacteroidetes/Firmicutes-ratio and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacteroidetes/Firmicutes-ratio and hepatic insulin sensitivity
Trial: 28619116
Drug: Individual low-threshold
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual low-threshold physical activity intervention with counseling from a personal coach during and 3 months after chemotherapy
Trial: 28620382
Drug: CSF-470 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSF-470 vaccine plus Bacillus Calmette-Guerin (BCG) and recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF)
Trial: 28620382
Drug: Medium-dose Interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose Interferon Alpha 2B
Trial: 28620471
Drug: Plant sterol-enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol-enriched spread (3 g/d)
Trial: 28622099
Drug: Concurrent use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent use of energy drinks with alcohol
Trial: 28622099
Drug: Energy drinks
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy drinks without concurrent alcohol use
Trial: 28622450
Drug: Oesophageal Capsule
RxNorm normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oesophageal Capsule Endoscopy (ECE)
Trial: 28622454
Drug: Tocilizumab (intravenous)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (intravenous)
Trial: 28622959
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg on days 1 to 21 and panobinostat 15 mg TIW for phase II
Trial: 28622959
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg and panobinostat 20 mg
Trial: 28622959
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of panobinostat and lenalidomide
Trial: 28623902
Drug: Optimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal treatment as specified in international guidelines
Trial: 28623988
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg/d) for EHIT prophylaxis
Trial: 28623995
Drug: Current treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current treatment approaches for SVT (including oral and injectable anticoagulants, pain medication, compression therapy, and no treatment)
Trial: 28625777
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab (Herceptin) 600 mg fixed-dose every 3 weeks for 18 cycles
Trial: 28629395
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) therapy initiated based on EASL criteria; 74 patients (24.7%) started TDF therapy, 46 (62.2%) had cirrhosis.
Trial: 28629466
Drug: Stromal vascular
RxNorm normalized name: Autologous stromal vascular fraction from adipose tissue
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stromal vascular fraction (SVF) and platelet rich plasma (PRP) intra-articular injection
Trial: 28629584
Drug: Met the
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Met the vitamin D estimated average requirement (EAR) intake (10 μg/d)
Trial: 28629584
Drug: Sufficient serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufficient serum 25-hydroxyvitamin D (25(OH)D) (≥50 nmol/L)
Trial: 28629584
Drug: Serum levels
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum levels at risk for inadequacy or deficiency (<50 nmol/L)
Trial: 28630120
Drug: TPO agonists
RxNorm normalized name: Tpoxx
DrugBank: Tecovirimat (DB12020)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TPO agonists
Trial: 28630121
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human thrombopoietin (rhTPO) therapy
Trial: 28630212
Drug: Stereotactic Body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic Body Radiation Therapy (SBRT) combined with Cytoreductive Nephrectomy
Trial: 28630876
Drug: SIB-IMRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIB-IMRT with doses of 69Gy, 75Gy, and 81Gy in 30 fractions to the internal gross tumor volume (iGTV)
Trial: 28630876
Drug: Standard IMRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard IMRT plans prescribed a dose of 60Gy to the planning tumor volume (PTV)
Trial: 28632462
Drug: Group Integrated
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Integrated Cognitive-Behavioral Therapy (ICBT)
Trial: 28633365
Drug: Copanlisib administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copanlisib administered intravenously on days 1, 8, and 15 of a 28-day cycle
Trial: 28634491
Drug: Daily growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily growth hormone treatment (group A, 16 patients)
Trial: 28634491
Drug: Three-times-weekly growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-times-weekly growth hormone treatment (group B, 16 patients)
Trial: 28637445
Drug: Standard local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard local practice treatment for posterior fossa tumours
Trial: 28638328
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia with intravenous infusion of propofol and maintenance with isoflurane for 3 hours
Trial: 28639987
Drug: Unfractioned heparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfractioned heparin, GPIs, bivalirudin
Trial: 28642315
Drug: Aclidinium bromide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium bromide, dosage and duration not available
Trial: 28642620
Drug: Pomalidomide (1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide (1-4 mg days 1-14), bortezomib (1-1.3 mg/m2), low-dose dexamethasone (LoDEX)
Trial: 28642620
Drug: Bortezomib (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (subcutaneous (SC) or intravenous (IV))
Trial: 28642620
Drug: Low-dose dexamethasone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dexamethasone (LoDEX)
Trial: 28642820
Drug: Standard tyrosine
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard tyrosine kinase inhibitors (TKI)
Trial: 28642891
Drug: VX15/2503 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VX15/2503 (1, 3, 6, 10, or 20 mg/kg)
Trial: 28643275
Drug: Once-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing of nitisinone
Trial: 28643275
Drug: Twice-daily dosing
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily dosing of nitisinone
Trial: 28644367
Drug: Cholic acid
RxNorm normalized name: Cholic Acid
DrugBank: Cholic Acid (DB02659)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cholic acid (10 to 15 mg·kg·day)
Trial: 28645776
Drug: Gilteritinib (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gilteritinib (oral, once daily) at various doses (20 mg, 40 mg, 80 mg, 120 mg, 200 mg, 300 mg, or 450 mg)
Trial: 28645776
Drug: Gilteritinib (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gilteritinib (oral, once daily) at various doses
Trial: 28645776
Drug: Gilteritinib (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gilteritinib (oral, once daily)
Trial: 28645937
Drug: Guideline-recommended treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-recommended treatments for ST-elevation myocardial infarction
Trial: 28645937
Drug: Defect-free rate
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defect-free rate of guideline-recommended treatments
Trial: 28646344
Drug: Chemotherapy A+B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy A+B (after biomarker information)
Trial: 28646344
Drug: Chemotherapy A
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy A alone (without biomarker information)
Trial: 28646344
Drug: Switch in
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch in treatment preference (after biomarker information)
Trial: 28647272
Drug: Withdrawal or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal or withholding of life-sustaining therapy (WWLST) discussions
Trial: 28648122
Drug: Dacomitinib 45-mg
RxNorm normalized name: dacomitinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacomitinib 45-mg oral dose
Trial: 28652228
Drug: Immediate intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate intervention group (n=17) received education session, Fitbit Flex, and weekly telephone counselling.
Trial: 28653250
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy (initiated by 990 survivors with estrogen-receptor-positive cancers)
Trial: 28653504
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) site (n=2,286)
Trial: 28654207
Drug: Grape polyphenols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape polyphenols (resveratrol, grape seed extract, grape juice; 2125 mg total polyphenols)
Trial: 28654347
Drug: PulmoBind, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PulmoBind, a ligand of the adrenomedullin receptor, used for molecular imaging of pulmonary circulation.
Trial: 28654574
Drug: Capecitabine 1000
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m² twice daily and Celecoxib 200 mg twice daily, day 1 to day 14 on a 21-day cycle
Trial: 28655452
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (AA) 1000 mg twice daily with prednisone (P) 5 mg twice daily after progression from standard-dose therapy.
Trial: 28655452
Drug: Standard-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose therapy of Abiraterone acetate (AA) 1000 mg daily with prednisone (P) 5 mg twice daily.
Trial: 28656110
Drug: 2G (760
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2G (760 mg of n-3 FA)
Trial: 28656110
Drug: 3G (1140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3G (1140 mg of n-3 FA)
Trial: 28656468
Drug: Self-administered implementation
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered implementation intention group
Trial: 28657941
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with pathologic complete response (pCR)
Trial: 28657941
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with residual disease
Trial: 28657941
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with pCR and residual disease
Trial: 28660406
Drug: Paliperidone extended-release
RxNorm normalized name: Paliperidone Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone extended-release (ER) 6 mg/day, titrated between 1.5 and 12 mg/day based on clinical response and tolerability
Trial: 28662033
Drug: Pazopanib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib + escalating doses of 131I
Trial: 28662684
Drug: Continuous high-intensity
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous high-intensity interval cycle ergometer exercises with short-acting insulin doses reduced by 25%, 50%, and 75%.
Trial: 28664499
Drug: Romidepsin 9
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin 9 mg/m²
Trial: 28664499
Drug: Romidepsin 14
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin 14 mg/m²
Trial: 28664507
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy (ET) in RS ≤ 11 patients
Trial: 28664507
Drug: Chemotherapy (anthracycline-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (anthracycline-containing or anthracycline-free) in RS 12-25 patients
Trial: 28664507
Drug: Chemotherapy (anthracycline-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (anthracycline-containing or anthracycline-free) in RS > 25 patients
Trial: 28666990
Drug: Biological age
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological age gene score based on 1254 genes related to aging
Trial: 28667381
Drug: Prandial premixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prandial premixed therapy (PPT) - insulin lispro mix 50/50 thrice daily with meals
Trial: 28667381
Drug: Basal-bolus therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal-bolus therapy (BBT) - glargine at bedtime plus mealtime insulin lispro
Trial: 28667563
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (CON)
Trial: 28667569
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) 30, 50, or 70 mg/day for 104 weeks
Trial: 28667887
Drug: Low Amplitude
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Amplitude Seizure Therapy (LAP-ST, 0.5-0.6A)
Trial: 28668141
Drug: hs-cTn concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTn concentrations ≥ 14 ng/L
Trial: 28668141
Drug: Common low-risk
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common low-risk cutoff of 14 ng/L
Trial: 28668244
Drug: Sublingual allergen-specific
RxNorm normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual allergen-specific immunotherapy (SLIT) with Staloral 300 SR Der p and Der f 50/50% extract
Trial: 28668244
Drug: Sublingual allergen-specific
RxNorm normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual allergen-specific immunotherapy (SLIT)
Trial: 28669012
Drug: Lapatinib (2500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (2500 mg twice daily for two consecutive days per week)
Trial: 28670237
Drug: Adalimumab (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (160 mg at week 0, 80 mg at week 2, 40 mg every other week thereafter)
Trial: 28670355
Drug: Non-thermal laser
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-thermal laser therapy
Trial: 28673311
Drug: DSS in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSS in combination with a custom multi-pad electrode design
Trial: 28674057
Drug: Teicoplanin loading
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin loading dose (LD) of 600 mg and maintenance dose (MD) of 400 mg for ECMO patients not receiving continuous renal replacement therapy (CRRT)
Trial: 28674057
Drug: Teicoplanin loading
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin loading dose (LD) of 800 mg and maintenance dose (MD) of 600 mg for ECMO patients receiving CRRT
Trial: 28674057
Drug: Teicoplanin loading
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin loading dose (LD) of 1,000 mg and maintenance dose (MD) of 800 mg for ECMO patients not receiving CRRT
Trial: 28674057
Drug: Teicoplanin loading
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin loading dose (LD) of 1,200 mg and maintenance dose (MD) of 1,000 mg for ECMO patients receiving CRRT
Trial: 28674140
Drug: BTT1023 (anti-VAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTT1023 (anti-VAP monoclonal antibody)
Trial: 28674870
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment (doses converted to haloperidol equivalents)
Trial: 28674982
Drug: Traditional pharmaceuticals
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Traditional pharmaceuticals
Trial: 28674982
Drug: Gene therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapies
Trial: 28674982
Drug: Antisense therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antisense therapies targeting familial forms of ALS
Trial: 28675695
Drug: Integrated psychological
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated psychological intervention (IPI) including cognitive behavioural therapy (CBT) and supportive counselling (SC) for 12 months
Trial: 28676651
Drug: D-dimer testing
RxNorm normalized name: dimer dilinoleyl dimer dilinoleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-dimer testing with a fixed threshold of 0.25 mg/L FEU
Trial: 28676842
Drug: DBS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBS plus optimal drug therapy (DBS+ODT)
Trial: 28677510
Drug: Fibrate monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrate monotherapy
Trial: 28677510
Drug: Daily drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily drug intake
Trial: 28677510
Drug: Forgot to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forgot to take medication
Trial: 28677510
Drug: Stopped medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopped medication when cholesterol normal